850876-88-9 Usage
Description
RG7227, ITMN-191, and RO5190591 are small molecule inhibitors that target specific proteins and pathways involved in various diseases. They have been developed as potential therapeutic agents for the treatment of cancer and viral infections.
Uses
Used in Cancer Therapy:
RG7227, ITMN-191, and RO5190591 are used as targeted therapies for the treatment of various types of cancer. They work by inhibiting specific proteins and signaling pathways that are crucial for cancer cell growth and survival, leading to the suppression of tumor progression.
Used in Antiviral Therapy:
RG7227, ITMN-191, and RO5190591 are also used as antiviral agents for the treatment of viral infections, such as Hepatitis C. They target essential viral proteins and enzymes, inhibiting viral replication and reducing the viral load in infected individuals.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of RG7227, ITMN-191, and RO5190591, various drug delivery systems have been developed. These systems, including organic and metallic nanoparticles, aim to improve the delivery of these inhibitors to target tissues and cells, increasing their therapeutic potential.
Used in Pharmaceutical Research:
RG7227, ITMN-191, and RO5190591 are also used in pharmaceutical research as tools to study the molecular mechanisms underlying various diseases. Their ability to selectively target specific proteins and pathways makes them valuable for investigating the roles of these targets in disease pathogenesis and for identifying potential therapeutic targets for drug development.
Used in Diagnostic Applications:
These small molecule inhibitors can also be used in diagnostic applications, such as imaging techniques, to visualize the expression and activity of their target proteins in vivo. This can help in the early detection and monitoring of diseases, as well as in the assessment of treatment response.
Overall, RG7227, ITMN-191, and RO5190591 are versatile compounds with a wide range of potential applications in the fields of medicine, pharmaceutical research, and diagnostics. Their ability to target specific proteins and pathways involved in various diseases makes them promising candidates for the development of novel therapeutic agents and diagnostic tools.
Check Digit Verification of cas no
The CAS Registry Mumber 850876-88-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,0,8,7 and 6 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 850876-88:
(8*8)+(7*5)+(6*0)+(5*8)+(4*7)+(3*6)+(2*8)+(1*8)=209
209 % 10 = 9
So 850876-88-9 is a valid CAS Registry Number.
850876-88-9Relevant articles and documents
Process for the preparation of a macrocycle
-
Page/Page column 25, (2010/03/02)
The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula wherein R1 is an amino protecting group and X is halogen by way of a ring closing metathesis approach.
Process for the preparation of a macrocycle
-
Page/Page column 20-21, (2009/07/10)
The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula wherein R1 is an amino protecting group and X is halogen by way of a ring closing metathesis approach.
